Clinical Trial

Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China

Completed Phase 4
View on ClinicalTrials.gov →
Summary
This study evaluates the safety of the quadrivalent subunit influenza vaccine in individuals aged 3 years and older in Jiangsu Province, China. The primary objectives are to assess the occurrence of very rare adverse reactions (incidence \<0.01%), investigate the incidence of cerebral infarction following vaccination, and evaluate the incidence of systemic adverse events among participants aged 9 to 17 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-14.
Trial Details
NCT Number NCT07710586
Lead Sponsor Ab&B Bio-tech Co., Ltd.JS
Collaborators: Jiangsu Province Centers for Disease Control and Prevention
Conditions Influenza Vaccine
Enrollment 3,105 participants
Start Date 2024-11-15
Primary Completion 2025-05-29 (estimated)
Study Completion 2025-05-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-20